2,897 reports of this reaction
2.8% of all METHYLPHENIDATE HYDROCHLORIDE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for METHYLPHENIDATE HYDROCHLORIDE, manufactured by Sandoz Inc. There are 2,897 FDA adverse event reports linking METHYLPHENIDATE HYDROCHLORIDE to HEADACHE. This represents approximately 2.8% of all 101,957 adverse event reports for this drug.
Patients taking METHYLPHENIDATE HYDROCHLORIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for METHYLPHENIDATE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for METHYLPHENIDATE HYDROCHLORIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 2,897 FDA reports for METHYLPHENIDATE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.8% of all adverse event reports for METHYLPHENIDATE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience headache while taking METHYLPHENIDATE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.